Michael Lavery over at Piper Sandler noted Tilray (TLRY.TO, TLRY) reported US$185.8 million in Q3 2025 revenue, well below its $194.4M estimate, and that its $9.0M adjusted EBITDA was below the Piper Sandler $11.6M estimate.
Piper Sandler now expects F25 sales of $850-900M (prior: $950M to $1B), which reflects a $50M headwind from SKU rationalization and strategic initiatives, but already included some M&A contribution. In F3Q25, Piper Sandler noted, Tilray's Project 420 cost-savings initiative generated $20.6M of savings of its projected $33.0M in total savings. Lavery said: "We continue to expect gross margin improvement in its Beverage Alcohol segment from repatriated production and distributor consolidation, but top-line trends are challenged." He added: "We expect cannabis stocks (TLRY included) will likely continue to trade largely on US regulatory expectations".
Piper Sandler lowered its F25E sales from near $850M to near $840M, its F26E sales from near $895M to near $875M. It lowered its PT from $2 to $1, now using near 1x C26 EV/Sales (prior: nea 2x) on diminished US regulatory expectations. PS has a Neutral rating on the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.